Skip Nav Destination
Issues
15 June 2015
-
Cover Image
Cover Image
The cover shows head and neck squamous cell carcinoma (UMSCC1) xenograft tissue sections harvested after treatment with the dual PI3k/mTOR inhibitor PF-05212384. Immunohistochemical staining demonstrates a significant reduction in phospho-S6 fluorescence (green) with intravenous PF-05212384 treatment. For details, see the article by Leiker and colleagues on page 2792 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
20th Anniversary Commentary
CCR Translations
CCR Perspectives in Drug Approval
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Hyon-Zu Lee; Virginia E. Kwitkowski; Pedro L. Del Valle; M. Stacey Ricci; Haleh Saber; Bahru A. Habtemariam; Julie Bullock; Erik Bloomquist; Yuan Li Shen; Xiao-Hong Chen; Janice Brown; Nitin Mehrotra; Sarah Dorff; Rosane Charlab; Robert C. Kane; Edvardas Kaminskas; Robert Justice; Ann T. Farrell; Richard Pazdur
Molecular Pathways
Reviews
Cancer Therapy: Clinical
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Elena Gabriela Chiorean; Patricia LoRusso; Robert Matthew Strother; Jennifer R. Diamond; Anne Younger; Wells A. Messersmith; Lieve Adriaens; Liming Liu; Richard J. Kao; Albert Thomas DiCioccio; Ana Kostic; Russell Leek; Adrian Harris; Antonio Jimeno
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Naval Daver; Yanis Boumber; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes; Michael E. Rytting; Jitesh D. Kawedia; Jordan Basnett; Kirk S. Culotta; Zhihong Zeng; Hongbo Lu; Mary Ann Richie; Rebecca Garris; Lianchun Xiao; Wenbin Liu; Keith A. Baggerly; Elias Jabbour; Susan O'Brien; Jan Burger; Linda J. Bendall; Deborah Thomas; Marina Konopleva
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois; Susan Groshen; Julie R. Park; Daphne A. Haas-Kogan; Xiaodong Yang; Ethan Geier; Eugene Chen; Kathy Giacomini; Brian Weiss; Susan L. Cohn; M. Meaghan Granger; Gregory A. Yanik; Randall Hawkins; Jesse Courtier; Hollie Jackson; Fariba Goodarzian; Hiroyuki Shimada; Scarlett Czarnecki; Denice Tsao-Wei; Judith G. Villablanca; Araz Marachelian; Katherine K. Matthay
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Andres Forero-Torres; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Katherine E. Varley; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Vandana G. Abramson; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Yufeng Li; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Christos Vaklavas; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Nancy U. Lin; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Minetta C. Liu; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Hope S. Rugo; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Rita Nanda; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Anna M. Storniolo; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Tiffany A. Traina; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Sujata Patil; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Catherine H. Van Poznak; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Julie R. Nangia; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); William J. Irvin, Jr; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Helen Krontiras; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Jennifer F. De Los Santos; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Paul Haluska; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); William Grizzle; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Richard M. Myers; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Antonio C. Wolff; on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
Author Choice
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Markus Hansson; Peter Gimsing; Ashraf Badros; Titti Martinsson Niskanen; Hareth Nahi; Fritz Offner; Morten Salomo; Elisabeth Sonesson; Morten Mau-Sorensen; Yvonne Stenberg; Annika Sundberg; Ingrid Teige; Jan Van Droogenbroeck; Stina Wichert; Maurizio Zangari; Björn Frendeus; Magnus Korsgren; Martine Poelman; Guido Tricot
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Justin F. Gainor; Daniel S.W. Tan; Tomasso De Pas; Benjamin J. Solomon; Aziah Ahmad; Chiara Lazzari; Filippo de Marinis; Gianluca Spitaleri; Katherine Schultz; Luc Friboulet; Beow Y. Yeap; Jeffrey A. Engelman; Alice T. Shaw
Personalized Medicine and Imaging
Author Choice
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
Fabian Birzele; Edgar Voss; Adam Nopora; Konrad Honold; Florian Heil; Sabine Lohmann; Henk Verheul; Christophe Le Tourneau; Jean-Pierre Delord; Carla van Herpen; Devalingam Mahalingam; Andrew L. Coveler; Valerie Meresse; Stefan Weigand; Valeria Runza; Michael Cannarile
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Costanza Paoletti; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Yufeng Li; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Maria C. Muñiz; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Kelley M. Kidwell; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Kimberly Aung; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Dafydd G. Thomas; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Martha E. Brown; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Vandana G. Abramson; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); William J. Irvin, Jr; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Nancy U. Lin; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Minetta C. Liu; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Rita Nanda; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Julie R. Nangia; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Anna M. Storniolo; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Tiffany A. Traina; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Christos Vaklavas; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Catherine H. Van Poznak; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Antonio C. Wolff; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Andres Forero-Torres; on behalf of the Translational Breast Cancer Research Consortium (TBCRC); Daniel F. Hayes; on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
Cancer Therapy: Preclinical
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Inger S. Nijhof; Richard W.J. Groen; Willy A. Noort; Berris van Kessel; Regina de Jong-Korlaar; Joost Bakker; Jeroen J.L. van Bueren; Paul W.H.I. Parren; Henk M. Lokhorst; Niels W.C.J. van de Donk; Anton C.M. Martens; Tuna Mutis
Author Choice
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
Alwin G. Schuller; Evan R. Barry; Rhys D.O. Jones; Ryan E. Henry; Melanie M. Frigault; Garry Beran; David Linsenmayer; Maureen Hattersley; Aaron Smith; Joanne Wilson; Stefano Cairo; Olivier Déas; Delphine Nicolle; Ammar Adam; Michael Zinda; Corinne Reimer; Stephen E. Fawell; Edwin A. Clark; Celina M. D'Cruz
Biology of Human Tumors
Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma
Ayako Masaki; Takashi Ishida; Yasuhiro Maeda; Susumu Suzuki; Asahi Ito; Hisashi Takino; Hiroka Ogura; Haruhito Totani; Takashi Yoshida; Shiori Kinoshita; Tomoko Narita; Masaki Ri; Shigeru Kusumoto; Atsushi Inagaki; Hirokazu Komatsu; Akio Niimi; Ryuzo Ueda; Atae Utsunomiya; Hiroshi Inagaki; Shinsuke Iida
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy
Emese Zsiros; Priyanka Duttagupta; Denarda Dangaj; Hongzhe Li; Renee Frank; Thomas Garrabrant; Ian S. Hagemann; Bruce L. Levine; Carl H. June; Lin Zhang; Ena Wang; Francesco M. Marincola; Davide Bedognetti; Daniel J. Powell, Jr; Janos Tanyi; Michael D. Feldman; Lana E. Kandalaft; George Coukos
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Antonio Calles; Lynette M. Sholl; Scott J. Rodig; Ashley K. Pelton; Jason L. Hornick; Mohit Butaney; Christine Lydon; Suzanne E. Dahlberg; Geoffrey R. Oxnard; David M. Jackman; Pasi A. Jänne
SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer
Thomas T. Vellinga; Tijana Borovski; Vincent C.J. de Boer; Szabolcs Fatrai; Susanne van Schelven; Kari Trumpi; Andre Verheem; Nikol Snoeren; Benjamin L. Emmink; Jan Koster; Inne H.M. Borel Rinkes; Onno Kranenburg
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.